Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion.

Clinical trial NCT07766317 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07766317
Sponsor: Gritbio Medicine, Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumors Cancer

Start date: 2026-11-01
Primary completion: 2030-06-01
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.